


# Q1 2026 results

## Clinical trial appendix



# Disclosures

---

Certain statements contained in this presentation and in any accompanying oral presentation, other than statements of fact that are independently verifiable at the date hereof, may constitute forward-looking statements. Examples of such forward-looking statements include statements regarding BeOne's research, discovery, pre-clinical and clinical programs and plans.

Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeOne's ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; BeOne's ability to achieve commercial success for its marketed medicines and drug candidates, if approved; BeOne's ability to obtain and maintain protection of intellectual property for its medicines and technology; BeOne's reliance on third parties to conduct drug development, manufacturing, commercialization and other services; BeOne's limited experience in obtaining regulatory approvals and commercializing pharmaceutical products; BeOne's ability to obtain additional funding for operations and to complete the development of its drug candidates and maintain profitability; and those risks more fully discussed in the section entitled "Risk Factors" in BeOne's most recent periodic report filed with the U.S. Securities and Exchange Commission ("SEC"), as well as discussions of potential risks, uncertainties, and other important factors in BeOne's subsequent filings with the SEC.

All information in this presentation is as of the date of this presentation, and BeOne undertakes no duty to update such information unless required by law.



# BeOne portfolio and pipeline snapshot

As of: 01 May 2026

**35+**

**Clinical  
and commercial  
-stage assets**

**80+**

**Approvals for  
BRUKINSA®  
(zanubrutinib)  
in countries globally**

**50+**

**Approvals for  
TEVIMBRA®  
(tislelizumab)  
in countries globally**

**180+**

**Total  
clinical trials  
conducted**

**30,000+**

**Patients  
enrolled in clinical  
trials globally\***

## Across three therapy areas:

**Hematology**



**Solid Tumor**



**Inflammation  
and Immunology**



\* Including IITs



# Project movements since Q4 2025 update

As of: 01 May 2026

New to Phase I/Ib	New to Phase II	New to pivotal trial	Accepted submission <i>Select markets</i> (AUS, U.S., BR, CA, CN, EU, JP, UK)	Approved <i>Select markets</i> (AUS, U.S., BR, CA, CN, EU, JP, UK)
<p><b>KLRG1 mAb</b> BG-A3004-101 immunology and inflammation</p> <p><b>ADAM9 ADC</b> BG-C0979-101 solid tumors</p>		<p><b>GPC3 x 4-1BB bsAb</b> BGB-B2033-101 3L+ HCC<sup>1</sup></p>	<p><b>Tislelizumab</b> Alt Dosing Q6W - CN ZW25-301 1L HER2+ GEA - CN, U.S. 309 1L NPC - JP</p> <p><b>Zanubrutinib</b> 214 R/R MZL - JP 114 Tablet - JP</p> <p><b>Zanidatamab</b> 301 1L HER2+ GEA - CN</p>	<p><b>Tislelizumab</b> 302 2L ESCC - CA 309 1L NPC - UK 312 1L ES-SCLC - UK 315 Neo-adj/adj NSCLC - UK</p> <p><b>Zanubrutinib</b> 114 Tablet formulation - UK</p> <p><b>Tarlatamab</b> 20230273 3L+ ES-SCLC - CN</p>

<sup>1</sup>Potentially pivotal  
CA - Canada; CN - China; EU - European Union; JP - Japan; UK - United Kingdom; U.S. - United States



# Projects removed since Q4 2025 update

As of: 01 May 2026

## Removed from Phase I

### **EGFR CDAC**

(BG-60366-101) lung cancers

### **Pan-KRASI**

(BGB-53038-101) GI and lung cancers

### **CCR8 mAb<sup>1</sup>**

(BGB-A3055-101) solid tumors

### **MAT2Ai**

(BG-89894-101) lung and solid tumors

### **CDK2i**

(BG-68501-101) Breast and solid tumors

## Removed from Phase II

### **IRAK4 CDAC**

(BGB-45035-201) Rheumatoid Arthritis


## Removed from Phase III

<sup>1</sup>Termination applied to the PhI study only and does not reflect discontinuation of the asset



# Global clinical development pipeline

As of: 01 May 2026



<sup>1</sup> DualityBio collaboration, <sup>2</sup>Amgen collaboration, <sup>3</sup>Zymeworks/Jazz collaboration  
Please refer to our most recent 10-K filing for a full list of our commercial products, including in-licensed products, as well as commercial rights and collaboration details



# Our ST pipeline includes diverse modalities and mechanisms across disease franchises

As of: 01 May 2026

## Breast/Gynecologic



CDK4i

B7-H4 ADC<sup>3</sup>

CDK2 CDAC

KAT6A/Bi

BCL2i (21447)

Claudin 6 x CD3 bsAb

## Lung



PRMT5i

CEA ADC

EGFR x MET x MET tsAb

EGFR x MET x MET tsADC

ADAM9 ADC

PD-1 x VEGF-A x CTLA-4 tsAb<sup>1,2</sup>

B7-H3 x ITGB6 bsADC<sup>1</sup>

KEAPI activator<sup>1</sup>

## Gastrointestinal



GPC3 x 4-1BB bsAb

PRMT5i

CEA ADC

FGFR2b ADC

HPK1i

RAS(ON)i<sup>1</sup>

<sup>1</sup> Expected to enter the clinic in 2026

<sup>2</sup> Huahui Health collaboration

<sup>3</sup> DualityBio collaboration



# Building leadership in solid tumors with innovative NMEs

As of: 01 May 2026

	Phase 1			Phase 2	Phase 3		Approved <sup>1</sup>
<b>Breast/ Gynecologic Cancers</b>	<b>BGB-C9074-101</b> B7-H4 ADC Breast (other ST)	<b>BGB-43395-101/102</b> CDK4i Breast (other ST)	<b>BGB-21447-102</b> BCL2i Breast				
	<b>BGB-B455-101</b> Claudin 6 x CD3 bsAb Gyn (other ST)	<b>BGB-75098-101</b> CDK2 CDAC Breast and Gyn.	<b>BGB-75202-101</b> KAT6A/Bi Breast				
<b>Gastro- intestinal</b>	<b>BGB-B2033-101</b> GPC3 x 4-1BB bsAb GI and Lung	<b>BG-C137-101</b> FGFR2b ADC GI and Lung	<b>BG-C477-101</b> CEA ADC GI and Lung				
	<b>BGB-26808-101</b> HPK1i GI						
<b>Lung</b>	<b>AMG757 20240124</b> Tarlatabab DLL3 x CD3 BiTE® 2L+ SCLC (+B7-H3) (Global)	<b>AMG757 20230298</b> Tarlatabab DLL3 x CD3 BiTE® 2L+ SCLC (SubQ) (Global)	<b>BG-T187-101</b> EGFR x MET x MET tsAb Lung and GI	<b>AMG757 20240092</b> Tarlatabab DLL3 x CD3 BiTE® 2L+ SCLC (Alt dosing) (Global)	<b>AMG757 20230016</b> Tarlatabab DLL3 x CD3 BiTE® LS-SCLC (Global)	<b>AMG757 20210004</b> Tarlatabab DLL3 x CD3 BiTE® 2L SCLC (Global)	<b>AMG757 20230273</b> Tarlatabab DLL3 x CD3 BiTE® 3L+ SCLC (CN) <sup>2</sup>
	<b>BGB-58067-101</b> MTA-coop. PRMT5i Lung and GI	<b>BG-C0902-101</b> EGFR x MET x MET tsADC Lung and GI	<b>BG-C0979-101</b> ADAM9 ADC Solid tumors		<b>AMG757 20240178</b> Tarlatabab DLL3 x CD3 BiTE® 1L ES-SCLC Induction. + Maint. (Global)	<b>AMG757 20200041</b> Tarlatabab DLL3 x CD3 BiTE® 1L ES-SCLC Maintenance. (Global)	
<b>Other</b>	<b>AMG509 20180146</b> Xaluritamig STEAPI x CD3 XmAb® mCRPC (Global)						

<sup>1</sup> Approved in at least one major market, such as U.S., CN, EU, and/or JP

<sup>2</sup> Conditional approval

Studies in "close-out" status excluded

Refer to Glossary abbreviations



# Building leadership in solid tumors with LCM

As of: 01 May 2026

	Phase 1	Phase 2	Phase 3		Approved <sup>1</sup>		
<b>Breast/ Gynecologic Cancers</b>					<b>Baituwei (Goserelin)</b> Breast, Prostate		
<b>Gastro- intestinal</b>		<b>BGB-A317-209</b> <b>Tislelizumab PD-1 mAb</b> Resect MSI-H/ dMMR CRC	<b>ZWI-ZW25-301</b> <b>Zanidatamab HER2 bsAb</b> 1L HER2+ GEA	<b>JZP598-302</b> <b>Zanidatamab HER2 bsAb</b> 1L BTC <sup>3</sup>	<b>BGB-A317-301</b> <b>Tislelizumab PD-1 mAb</b> 1L HCC	<b>BGB-A317-302</b> <b>Tislelizumab PD-1 mAb</b> 2L ESCC	<b>BGB-A317-305</b> <b>Tislelizumab PD-1 mAb</b> 1L GC
					<b>BGB-A317-306</b> <b>Tislelizumab PD-1 mAb</b> 1L ESCC	<b>BGB-A317-208</b> <b>Tislelizumab PD-1 mAb</b> 2L/3L+HCC	<b>ZWI-ZW25-203</b> <b>Zanidatamab HER2 bsAb</b> HER2+ 2L+ BTC (CN) <sup>2</sup>
<b>Lung</b>					<b>BGB-A317-304</b> <b>Tislelizumab PD-1 mAb</b> 1L Non-sq. NSCLC	<b>BGB-A317-307</b> <b>Tislelizumab PD-1 mAb</b> 1L Sq. NSCLC	<b>BGB-A317-303</b> <b>Tislelizumab PD-1 mAb</b> 2/3L NSCLC
					<b>BGB-A317-312</b> <b>Tislelizumab PD-1 mAb</b> 1L ES-SCLC	<b>BGB-A317-309</b> <b>Tislelizumab PD-1 mAb</b> 1L NPC	<b>BGB-A317-315</b> <b>Tislelizumab PD-1 mAb</b> Neo/adj. NSCLC
<b>Other</b>			<b>BGB-A317-310</b> <b>Tislelizumab PD-1 mAb</b> 1L UBC	<b>BGB-A317-290-LTE1</b> <b>Multiple assets</b> LTE Solid Tumors	<b>BGB-A317-204</b> <b>Tislelizumab PD-1 mAb</b> 2L UC	<b>BGB-A317-209</b> <b>Tislelizumab PD-1 mAb</b> Late Line MSI-H or dMMR	
			<b>BGB-A317-316</b> <b>Tislelizumab PD-1 mAb</b> SubQ Formulation				

<sup>1</sup> Approved in at least one major market, such as U.S., CN, EU, and/or JP

<sup>2</sup> Conditional approval

<sup>3</sup> Confirmatory trial for ZWI-ZW25-203 2L+ BTC

Refer to Glossary abbreviation

Studies in "close-out" status excluded



# A leader in hematology

As of: 01 May 2026

	Phase 1		Phase 2	Phase 3		Approved <sup>1</sup>	
<b>AML/MDS, Multiple Myeloma, Other Heme</b>	<b>BGB-11417-103</b> Sonrotoclax BCL2i AML/MDS	<b>BGB-11417-105</b> Sonrotoclax BCL2i R/R Multiple Myeloma t(11;14)	<b>BLINCYTO</b> CD19 x CD3 BiTE® R/R and MRD+ B-ALL (Subq)				
<b>B-Cell</b>	<b>BGB-11417-101</b> Sonrotoclax BCL2i mono & combo w/zanu	<b>BGB-11417-102</b> Sonrotoclax BCL2i B-Cell Malig.(CN)	<b>BGB-3111-304</b> Zanubrutinib BTKi TN CLL Ven combo	<b>BGB-3111-306</b> Zanubrutinib BTKi TN MCL	<b>BGB-3111-308</b> Zanubrutinib BTKi R/R MZL, R/R FL	<b>BGB-3111-206</b> Zanubrutinib BTKi R/R MCL <sup>2</sup>	<b>BGB-3111-302</b> Zanubrutinib BTKi TN & R/R WM
	<b>BGB-11417-108</b> Sonrotoclax BCL2i B-Cell Malig. dose ramp-up	<b>BGB-16673-101</b> BTK CDAC B-Cell Malig.	<b>BGB-11417-203</b> Sonrotoclax BCL2i R/R WM	<b>BGB-3111-LTE1</b> Zanubrutinib BTKi B-cell malignancies		<b>BGB-3111-212</b> Zanubrutinib BTKi R/R FL <sup>2</sup>	<b>BGB-3111-304</b> Zanubrutinib BTKi TN CLL/SLL
	<b>BGB-16673-102</b> BTK CDAC B-Cell Malig. (CN)	<b>BGB-16673-104</b> BTK CDAC B-Cell Malig. combos	<b>BGB-16673-101/102</b> BTK CDAC R/R CLL & R/R WM (exp.)	<b>BGB-11417-301</b> Sonrotoclax BCL2i TN CLL + zanu	<b>BGB-11417-302</b> Sonrotoclax BCL2i R/R MCL	<b>BGB-3111-214</b> Zanubrutinib BTKi R/R MZL <sup>2</sup>	<b>BGB-3111-305</b> Zanubrutinib BTKi R/R CLL/SLL
			<b>BGB-11417-204</b> Sonrotoclax BCL2i TN CLL	<b>BGB-11417-303</b> Sonrotoclax BCL2i R/R CLL/SLL	<b>BGB-11417-304</b> Sonrotoclax BCL2i TN CLL + zanu vs. AV	<b>BGB-3111-114</b> Zanubrutinib BTKi Tablet formulation	
				<b>BGB-16673-302</b> BTK CDAC R/R CLL	<b>BGB-16673-303</b> BTK CDAC R/R CLL (CN)	<b>BGB-11417-202</b> Sonrotoclax BCL2i R/R CLL(CN) <sup>2</sup>	<b>BGB-11417-201</b> Sonrotoclax BCL2i R/R MCL <sup>2</sup>
				<b>BGB-16673-304</b> BTK CDAC R/R CLL vs. pirtobrutinib			

<sup>1</sup> Approved in at least one major market, such as U.S., CN, EU, and/or JP

<sup>2</sup> Conditional approval

Studies in "close-out" status excluded

Refer to Glossary abbreviation

Blinicyto 20190359 (post marketing) is not included in this view



# I&I portfolio

As of: 01 May 2026

	Phase 1	Phase 2	Phase 3
I&I	<p><b>BGB-45035-101</b> <b>IRAK4 CDAC</b> HV &amp; AD, PN</p> <p><b>BG-A3004-101</b> <b>KLRG1 mAb</b> I&amp;I (CN)</p>		<p><b>BGB-3111-309</b> <b>Zanubrutinib BTKi</b> PMN</p>

Studies in "close-out" status excluded  
Refer to Glossary abbreviation



# Trial detail

- **BRUKINSA<sup>®</sup>** (zanubrutinib)
- **Sonrotoclax**
- **BGB-16673 BTK CDAC**
- **Other hematology assets**
- **TEVIMBRA<sup>®</sup>** (tislelizumab)
- **Other solid tumor assets**
- **Immunology and inflammation assets**



# BRUKINSA®

## Foundational asset in hematology portfolio

As of: 01 May 2026

Trial	Phase	CT.gov	Population	Total patients <sup>1</sup>	Combination molecule(s)	Primary endpoint(s)	Status
BGB-3111-304 (SEQUOIA)	Phase 3	NCT03336333	TN CLL/SLL	784	Venetoclax (arm D)	PFS	Approved <sup>2</sup> / Maint. (arm D)
BGB-3111-306 (MANGROVE)	Phase 3	NCT04002297	TN MCL	510	Rituximab	PFS	Maintenance
BGB-3111-308 (MAHOGANY)	Phase 3	NCT05100862	R/R MZL and FL	780	Rituximab, Obinutuzumab	PFS	Enrolling
BGB-3111-LTE1	Phase 3	NCT04170283	B-Cell Malignancies	956		TEAEs	Maintenance
BGB-3111-114	Phase 1	NCT05767398	Healthy volunteers	58	-	PK	Approved <sup>2</sup>
BGB-3111-206	Phase 2	NCT03206970	R/R MCL	86	-	ORR	Approved <sup>2</sup>
BGB-3111-212 (ROSEWOOD)	Phase 2	NCT03332017	R/R FL	217	Obinutuzumab	ORR	Approved <sup>2</sup>
BGB-3111-214 (MAGNOLIA)	Phase 2	NCT03846427	R/R MZL	68	-	ORR	Approved <sup>2</sup>
BGB-3111-302 (ASPEN)	Phase 3	NCT03053440	TN and R/R WM	229	-	CR\VGPR	Approved <sup>2</sup>
BGB-3111-305 (ALPINE)	Phase 3	NCT03734016	R/R CLL	652	-	ORR	Approved <sup>2</sup>



<sup>1</sup> Enrollment numbers represent planned enrollment for ongoing trials or actual enrollment for maintenance, close-out, or approved trials

<sup>2</sup> Approved in at least one major market, such as the U.S., EU, China and/or Japan

Refer to Glossary abbreviations



# Sonrotoclax

## Potential best-in-class BCL2 inhibitor with differentiated profile

As of: 01 May 2026

Trial	Phase	CT.gov	Population	Total patients <sup>1</sup>	Combination molecule(s)	Primary endpoint(s)	Status
BGB-11417-101	Phase 1	NCT04277637	B-Cell Malignancies & NHL	437	Zanubrutinib, Obinutuzumab	TEAEs, MTD	Maintenance
BGB-11417-102	Phase 1	NCT04883957	B-Cell Malignancies	64 (CN)	-	TEAEs, MTD	Maintenance
BGB-11417-103	Phase 1	NCT04771130	AML/MDS	260	Azacitidine	TEAEs, CR, mOR	Enrolling
BGB-11417-105	Phase 1	NCT04973605	R/R MM with t(11;14)	246	Dexamethasone, Carfilzomib, Daratumumab, Pomalidomide	TEAEs, ORR, VGPR, CR	Enrolling
BGB-11417-108	Phase 1/2	NCT06697184	B-Cell Malignancies	58	Zanubrutinib	TLS	Maintenance
BGB-11417-203	Phase 2	NCT05952037	R/R WM	114	Zanubrutinib	MRR	Maintenance
BGB-11417-204	Phase 2	NCT06637501	TN CLL	94	Zanubrutinib	CR/CRi	Maintenance
BGB-11417-301 (CELESTIAL-TNCLL)	Phase 3	NCT06073821	TN CLL/SLL (+Zanu)	711	Zanubrutinib	PFS	Maintenance
BGB-11417-302 (CELESTIAL-RRMCL)	Phase 3	NCT06742996	R/R MCL	300	Zanubrutinib	PFS	Enrolling
BGB-11417-303 (CELESTIAL-RRCLL)	Phase 3	NCT06943872	R/R CLL/SLL	630	Obinutuzumab, Rituximab	PFS	Enrolling
BGB-11417-304 (CELESTIAL-TNCLL2)	Phase 3	NCT07277231	TN CLL (vs acala + ven)	500	Zanubrutinib	PFS	Enrolling
BGB-11417-201	Phase 2	NCT05471843	R/R MCL	124	-	TEAEs, ORR	Approved CN; Maintenance ROW
BGB-11417-202	Phase 2	NCT05479994	R/R CLL	100	-	ORR	Approved <sup>2</sup>

<sup>1</sup> Enrollment numbers represent planned enrollment for ongoing trials or actual enrollment for maintenance, close-out, or approved trials

<sup>2</sup> Approved in at least one major market, such as the U.S., EU, China and/or Japan

Refer to Glossary abbreviations



# BGB-16673 BTK CDAC

## Potential first-in-class and best-in-class BTK degrader

As of: 01 May 2026

Trial	Phase	CT.gov	Population	Total patients <sup>1</sup>	Combination molecule(s)	Primary endpoint(s)	Status
<b>BGB-16673-101</b> (CaDAnCe-101)	<b>Phase 1/2</b>	NCT05006716	B-Cell Malignancies	614	-	TEAEs	Enrolling
<b>BGB-16673-102</b>	<b>Phase 1/2</b>	NCT05294731	B-Cell Malignancies	146	-	TEAEs, RP2D, ORR	Enrolling
<b>BGB-16673-104</b> (CaDAnCe-104)	<b>Phase 1/2</b>	NCT06634589	B-Cell Malignancies	80	Sonrotoclax, Zanubrutinib, Mosunetuzumab, Glofitamab	DLTs, TEAEs	Enrolling
<b>BGB-16673-302</b> (CaDAnCe-302)	<b>Phase 3</b>	NCT06846671	R/R CLL/SLL (investigators choice)	250	-	PFS	Enrolling
<b>BGB-16673-303</b> (CaDAnCe-303)	<b>Phase 3</b>	NCT06970743	R/R CLL/SLL (CN)	150	-	PFS	Enrolling
<b>BGB-16673-304</b> (CaDAnCe-304)	<b>Phase 3</b>	NCT06973187	R/R CLL/SLL (vs pirtobrutinib)	500	-	PFS	Enrolling

<sup>1</sup> Enrollment numbers represent planned enrollment for ongoing trials or actual enrollment for maintenance, close-out, or approved trials  
Refer to Glossary abbreviations



# Phase 1 and 2 – other hematology assets

As of: 01 May 2026

Trial	MOA	Phase	CT.gov	Population	Total patients <sup>1</sup>	Combination molecule(s)	Primary endpoint(s)	Status
<b>BGB-21447-101</b>	BCL2i	<b>Phase 1</b>	NCT05828589	B-cell malignancies	52	-	DLTs, AEs, TLS	Closeout
<b>BLINCYTO® 20180257</b>	CD19 x CD3 BiTE®	<b>Phase 2</b>	NCT04521231	R/R and MRD+ B-ALL	281 <sup>2</sup>	-	CR/CRh, CR, MRD	Enrolling
<b>BLINCYTO® 20190359</b>	CD19 x CD3 BiTE®	<b>Phase 2</b>	NCT06054113	Pediatric R/R B-ALL	18	-	CR/CRh	Maintenance

<sup>1</sup> Enrollment numbers represent planned enrollment for ongoing trials or actual enrollment for maintenance, close-out, or approved trials

<sup>2</sup> Total planned enrollment, with BeOne territories included

Refer to Glossary abbreviations



# TEVIMBRA®

## Poised for global patient impact

As of: 01 May 2026

Trial	Phase	CT.gov	Population	Total patients <sup>1</sup>	Combination molecule(s)	Primary endpoint(s)	Status
BGB-A317-103	Phase 1	NCT06091943	SubQ Formulation	59	-	Bioavailability and Safety	Closeout
BGB-HNSCC-201	Phase 2	NCT05909904	1L HNSCC	160	LAG3, TIM3	ORR	Closeout
BGB-LC-201	Phase 2	NCT05635708	1L NSCLC	418	LAG3, OX40, HPK1, Chemotherapy	ORR	Closeout
BGB-A317-316	Phase 3	NCT07043400	SubQ Formulation	351	Chemotherapy	PK	Enrolling
BGB-A317-310 (RATIONALE-310)	Phase 3	NCT03967977	1L UBC	420	Chemotherapy	OS (ITT)	Maintenance
BGB-A317-204	Phase 2	NCT04004221	2L UC	113	-	ORR	Approved <sup>2</sup>
BGB-A317-312 (RATIONALE-312)	Phase 3	NCT04005716	1L ES-SCLC	457	Chemotherapy	OS	Approved <sup>3</sup>
BGB-A317-315 (RATIONALE-315)	Phase 3	NCT04379635	Neo/adj NSCLC	453	Chemotherapy	MPR, EFS	Approved <sup>3</sup>



<sup>1</sup> Enrollment numbers represent planned enrollment for ongoing trials or actual enrollment for maintenance, close-out, or approved trials

<sup>2</sup> Approved only in China

<sup>3</sup> Approved in at least one major market, such as the U.S., EU, China and/or Japan

Refer to Glossary abbreviations



# TEVIMBRA®

## Poised for global patient impact

As of: 01 May 2026

Trial	Phase	CT.gov	Population	Total patients <sup>1</sup>	Combination molecule(s)	Primary endpoint(s)	Status
BGB-A317-208	Phase 2	NCT03419897	2L+ HCC	249	-	ORR	Approved <sup>2</sup>
BGB-A317-209	Phase 2	NCT03736889	Late Line MSI-H or dMMR Solid Tumors	150	-	ORR	Approved <sup>2</sup>
BGB-A317-301 (RATIONALE-301)	Phase 3	NCT03412773	1L HCC	684	-	OS	Approved <sup>3</sup>
BGB-A317-302 (RATIONALE-302)	Phase 3	NCT03430843	2L ESCC	513	-	OS	Approved <sup>3</sup>
BGB-A317-303 (RATIONALE-303)	Phase 3	NCT03358875	2/3L NSCLC	805	-	OS (PDL1+), OS	Approved <sup>3</sup>
BGB-A317-304 (RATIONALE-304)	Phase 3	NCT03663205	1L Non-sq. NSCLC	334	Chemotherapy	PFS	Approved <sup>3</sup>
BGB-A317-305 (RATIONALE-305)	Phase 3	NCT03777657	1L GC	997	Chemotherapy	OS	Approved <sup>3</sup>
BGB-A317-306 (RATIONALE-306)	Phase 3	NCT03783442	1L ESCC	649	Chemotherapy	OS	Approved <sup>3</sup>
BGB-A317-307 (RATIONALE-307)	Phase 3	NCT03594747	1L Sq. NSCLC	360	Chemotherapy	PFS	Approved <sup>3</sup>
BGB-A317-309 (RATIONALE-309)	Phase 3	NCT03924986	1L NPC	263	Chemotherapy	PFS	Approved <sup>3</sup>



<sup>1</sup> Enrollment numbers represent planned enrollment for ongoing trials or actual enrollment for maintenance, close-out, or approved trials

<sup>2</sup> Approved only in China

<sup>3</sup> Approved in at least one major market, such as the U.S., EU, China and/or Japan

Refer to Glossary abbreviations



# Phase 1 – other solid tumor assets

As of: 01 May 2026

Trial	Asset	MOA	Phase	CT.gov	Population	Total patients <sup>1</sup>	Combination molecule(s)	Primary endpoint(s)	Status
BGB-B455-101	BGB-B455	Claudin 6 x CD3 bsAb	Phase 1	NCT06803680	Solid Tumors	90	-	AE, SAE, DLT, MTD, RDFE, RP2D, ORR	Dose Escalation
BGB-58067-101	BGB-58067	PRMT5i	Phase 1	NCT06589596	Solid Tumors	244	-	AE, SAE, DLT, MTD, RDFE, RP2D, ORR	Dose Escalation
BG-T187-101	BG-T187	EGFR x MET x MET tsAb	Phase 1	NCT06598800	Solid Tumors	87	-	AE, SAE, DLT, MTD, RDFE, ORR	Dose Escalation
BG-C0902-101	BG-C0902	EGFR x MET x MET tsADC	Phase 1	NCT07181681	Solid Tumors	63	-	AE, SAE, DLT, MTD, RDFE, RP2D, ORR	Dose Escalation
BGB-21447-102	BGB-21447	BCL2i	Phase 1	NCT06756932	2L+ HR+/HER2- BC	120	BGB-43395 ± Fulvestrant	AE, SAE, DLT, MTD, RDFE, RP2D, ORR	Dose Escalation
BG-75098-101	BG-75098	CDK2 CDAC	Phase 1	NCT07226349	Solid Tumors	105	BGB-43395, Fulvestrant	AE, SAE, RDFE, ORR	Dose Escalation
BG-75202-101	BG-75202	KAT6A/Bi	Phase 1	NCT07222267	Solid Tumors	86	Estrogen receptor antagonist, CDK4i, aromatase inhibitor	AE, SAE, MTD, RDFE, ORR	Dose Escalation
BG-C137-101	BG-C137	FGFR2b ADC	Phase 1	NCT06625593	Solid Tumors	168	-	AE, SAE, DLT, MTD, RDFE, ORR	Dose Escalation
BG-C477-101	BG-C477	CEA ADC	Phase 1	NCT06596473	Solid Tumors	310	Chemotherapy	AE, SAE, DLT, MTD, RDFE, ORR	Dose Escalation
BG-C0979-101	BG-C0979	ADAM9 ADC	Phase 1	NCT07414836	Solid Tumors	84	Tislelizumab	AE, SAE, DLT, MTD, RDFE, RP2D, ORR	Dose Escalation
BGB-B2033-101	BGB-B2033	GPC3 x 4-1BB bsAb	Phase 1	NCT06427941	Solid Tumors	140	Tislelizumab	AE, SAE, DLT, MTD, RP2D	Dose Escalation

<sup>1</sup> Enrollment numbers represent planned enrollment for ongoing trials or actual enrollment for maintenance, close-out, or approved trials  
Refer to Glossary abbreviations



# Phase 1 – other solid tumor assets

As of: 01 May 2026

Trial	Asset	MOA	Phase	CT.gov	Population	Total patients <sup>1</sup>	Combination molecule(s)	Primary endpoint(s)	Status
BGB-43395-101	BGB-43395	CDK4i	Phase 1	NCT06120283	BC and Solid Tumors	399	Fulvestrant, Letrozole	AE, SAE, DLT, MTD, RDFE, ORR	Dose Expansion
BGB-43395-102	BGB-43395	CDK4i	Phase 1	NCT06253195	HR+/HER2- BC and Solid Tumors	33	Fulvestrant, Letrozole	AE, SAE, DLT, MTD, RDFE, ORR	Maintenance
BG-C9074-101	BGB-C9074	B7-H4 ADC	Phase 1	NCT06233942	Solid Tumors	308	Tislelizumab	TEAE, SAE, DLT, MTD, RDFE, ORR, RP2D	Dose Expansion
BGB-A317-26808-101	BGB-26808	HPK1i	Phase 1	NCT05981703	Solid Tumors	217	Tislelizumab	AE, SAE, DLT, MTD, RDFE, ORR	Dose Expansion
AMG757 20230298 (DeLLphi-308)	Tarlatamab	DLL3 x CD3 BiTE® (SubQ)	Phase 1	NCT06598306	2L+ SCLC	220 <sup>2</sup>	-	DLTs, SAEs, TEAEs	Enrolling
AMG509 20180146	Xaluritamig	STEAPI x CD3 XmAb®	Phase 1	NCT04221542	mCRPC	479 <sup>2</sup>	-	TEAEs, DLTs	Enrolling
AMG757 20240124 (DeLLphi-310)	Tarlatamab	DLL3 x CD3 BiTE® (+B7-H3)	Phase 1	NCT06898957	2L+ SCLC	200 <sup>2</sup>	YL201	DLTs, TEAEs	Enrolling
BGB-R046-101	BGB-R046	IL-15 prodrug	Phase 1	NCT06487858	Solid Tumors	42 (CN)	Tislelizumab	AE, SAE, DLT, MTD, RDFE, ORR	Closeout
BGB-A317-15025-101	BGB-15025	HPK1i	Phase 1	NCT04649385	Solid Tumors	157	Tislelizumab	AE, SAE, DLT, MTD, RDFE, ORR	Closeout
BGB-C354-101	BGB-C354	B7-H3 ADC	Phase 1	NCT06422520	Solid Tumors	63	Tislelizumab	AE, SAE, DLT, MTD, RDFE, ORR	Closeout
BG-60366-101	BG-60366	EGFR CDAC	Phase 1	NCT06685718	Solid Tumors	33	-	AE, SAE, DLT, MTD, RDFE, ORR	Closeout
BGB-53038-101	BGB-53038	Pan-KRASI	Phase 1	NCT06585488	Solid Tumors	47	Tislelizumab, Cetuximab	AE, SAE, DLT, MTD, RDFE, RP2D, ORR	Closeout
BG-89894-101	BG-89894	MAT2Ai	Phase 1	NCT06568614	Solid Tumors	29	-	AE, SAE, DLT, MTD, RDFE, RP2D, ORR	Closeout
BG-68501-101	BG-68501	CDK2i	Phase 1	NCT06257264	Solid Tumors	103	BGB-43395, Fulvestrant	AE, SAE, DLT, MTD, RDFE, ORR	Closeout

<sup>1</sup> Enrollment numbers represent planned enrollment for ongoing trials or actual enrollment for maintenance, close-out, or approved trials

<sup>2</sup> Total planned enrollment, with BeOne territories included

Refer to Glossary abbreviations



# Phase 2 – other solid tumor assets

As of: 01 May 2026

Trial	Asset	MOA	Phase	CT.gov	Population	Total patients <sup>1</sup>	Combination molecule(s)	Primary endpoint(s)	Status
<b>AMG757 20240092</b> (DeLLphi-309) (Alt dosing)	Tarlatamab	DLL3 x CD3 BiTE®	<b>Phase 2</b>	NCT06745323	2L SCLC	252	-	ORR	Maintenance
<b>BGB-A317-A445-201</b>	BGB-A445	OX40 mAb	<b>Phase 2</b>	NCT05661955	Melanoma, UC	113	Tislelizumab	ORR	Closeout
<b>BGB-LBL-007-201</b>	BGB-LBL-007	LAG3 mAb	<b>Phase 2</b>	NCT05609370	MSS-CRC	113	Tislelizumab, Chemotherapy, Bevacizumab	PFS, AE, SAE	Closeout
<b>BGB-LBL-007-202</b>	BGB-LBL-007	LAG3 mAb	<b>Phase 2</b>	NCT06010303	1L ESCC	118	Tislelizumab, Chemotherapy	ORR	Closeout
<b>AMG757 20230273</b> (DeLLphi-307)	Tarlatamab	DLL3 x CD3 BiTE®	<b>Phase 2</b>	NCT06502977	3L+ ES-SCLC	32 (CN)	-	ORR	Approved <sup>2</sup>
<b>ZWI-ZW25-203</b> (HERIZON-BTC-01)	Zanidatamab	HER2 bsAb	<b>Phase 2</b>	NCT04466891	2L+ BTC	87	-	ORR	Approved <sup>2</sup>

<sup>1</sup> Enrollment numbers represent planned enrollment for ongoing trials or actual enrollment for maintenance, close-out, or approved trials

<sup>2</sup> Approved only in China

Refer to Glossary abbreviations



# Phase 3 – other solid tumor assets

As of: 01 May 2026

Trial	Asset	MOA	Phase	CT.gov	Population	Total patients <sup>1</sup>	Combination molecule(s)	Primary endpoint(s)	Status
<b>AMG757 20240178</b> (DeLLphi-312) (Induction + Maintenance)	Tarlatamab	DLL3 x CD3 BiTE®	<b>Phase 3</b>	NCT07005128	1L ES-SCLC	330 <sup>2</sup>	Durvalumab +chemo (induction); Durvalumab (maintenance)	PFS, OS	Enrolling
<b>JZP598-302</b> (HERIZON-BTC-302)	Zanidatamab	HER2 bsAb	<b>Phase 3</b>	NCT06282575	1L BTC	286 <sup>3</sup>	Chemo ± Pembrolizumab/Durvalumab	PFS	Enrolling
<b>ZWI-ZW25-301</b> (HERIZON-GEA-01)	Zanidatamab	HER2 bsAb	<b>Phase 3</b>	NCT05152147	1L HER2+ GEA	438	Chemo ± Tislelizumab	PFS, OS	Maintenance
<b>BGB-A317-290-LTE1</b>	Internal assets	Multiple	<b>Phase 3</b>	NCT04164199	Multiple	404	Multiple	Immune mediated adverse events	Maintenance
<b>AMG757 20200041</b> (DeLLphi-305) (Maintenance)	Tarlatamab	DLL3 x CD3 BiTE®	<b>Phase 3</b>	NCT06211036	1L ES-SCLC	563 <sup>2</sup>	Durvalumab (maintenance)	OS	Maintenance
<b>AMG757 20210004</b> (DeLLphi-304)	Tarlatamab	DLL3 x CD3 BiTE®	<b>Phase 3</b>	NCT05740566	2L SCLC	509 <sup>2</sup>	-	OS	Maintenance
<b>AMG757 20230016</b> (DeLLphi-306)	Tarlatamab	DLL3 x CD3 BiTE®	<b>Phase 3</b>	NCT06117774	LS-SCLC	400 <sup>2</sup>	-	PFS, OS	Maintenance
<b>BGB-A317-A1217-302</b> (AdvantIG-302)	Ociperlimab	TIGIT mAb	<b>Phase 3</b>	NCT04746924	1L NSCLC (PD-L1 High)	669	Tislelizumab	OS	Closeout

<sup>1</sup> Enrollment numbers represent planned enrollment for ongoing trials or actual enrollment for maintenance, close-out, or approved trials

<sup>2</sup> Total planned enrollment, with BeOne territories included

<sup>3</sup> BeOne responsible for CN enrollment

Refer to Glossary abbreviations



# Immunology and inflammation assets

As of: 01 May 2026

Trial	MOA	Phase	CT.gov	Population	Total patients <sup>1</sup>	Combination molecule(s)	Primary endpoint(s)	Status
<b>BG-A3004-101</b>	KLRG1 mAb	<b>Phase 1</b>	NCT07412691	Healthy participants and patients with immune-mediated skin diseases	98	-	Incidence and severity of TEAEs and SAEs	Enrolling
<b>BGB-45035-101</b>	IRAK4 CDAC	<b>Phase 1</b>	NCT06342713	Healthy volunteers and patients with atopic dermatitis or prurigo nodularis	211	-	Incidence and severity of TEAEs	Enrolling
<b>BGB-45035-201</b>	IRAK4 CDAC	<b>Phase 2</b>	NCT07100938	Adults with moderate to severe active rheumatoid arthritis	49	-	Change from baseline in Disease Activity Score - C-reactive protein (DAS28-CRP) at Week 12	Maintenance
<b>BGB-16673-107</b>	BTK CDAC	<b>Phase 1</b>	NCT07005713	Chronic spontaneous urticaria (CSU)	34	-	Incidence and severity of TEAEs	Maintenance
<b>BGB-3111-309</b>	BTKi	<b>Phase 2/3</b>	NCT05707377	Primary Membranous Nephropathy	178	-	Urine Protein Creatinine Ratio, Complete Remission	Maintenance

<sup>1</sup> Enrollment numbers represent planned enrollment for ongoing trials or actual enrollment for maintenance, close-out, or approved trials  
Refer to Glossary abbreviations



# Full list of commercial and clinical assets

As of: 01 May 2026

## Commercial

Product	Commercial rights	Partner
<b>BRUKINSA® (zanubrutinib)</b>	Global	-
<b>TEVIMBRA® (tislelizumab)</b>	Global	-
<b>Sonrotoclax<sup>3</sup></b>	Global	-
<b>IMDELLTRA® (tarlatamab)<sup>1</sup></b>	China	Amgen
<b>XGEVA® (denosumab)</b>	China	Amgen
<b>BLINCYTO® (blinatumomab)</b>	China	Amgen
<b>KYPROLIS® (carfilzomib)</b>	China	Amgen
<b>ZIIHERA® (zanidatamab)</b>	APAC <sup>4</sup>	Zymeworks / Jazz
<b>SYLVANT® (siltuximab)</b>	China	Recordati
<b>QARZIBA® (dinutuximab)</b>	China	Recordati
<b>TAFINLAR® (dabrafenib)</b>	China	Novartis
<b>MEKINIST® (trametinib)</b>	China	Novartis
<b>VOTRIENT® (pazopanib)</b>	China	Novartis
<b>AFINITOR® (everolimus)</b>	China	Novartis
<b>ZYKADIA® (ceritinib)</b>	China	Novartis
<b>POBEVCY® (Avastin biosimilar)</b>	China	Bio-Thera
<b>BAITUOWEI® (goserelin microspheres for injection)</b>	China	Luye Pharma

## Pipeline

Asset	Latest stage	Partner	Asset	Latest stage	Partner
<b>BGB-16673 (BTK CDAC)</b>	Ph3	-	<b>BG-A3004 (KLRG1 mAb)</b>	Ph1	-
<b>BG-71332 (BTKi + BCL2i)<sup>5</sup></b>	Ph1	-	<b>BGB-45035 (IRAK4 CDAC)</b>	Ph2	-
<b>BGB-21447 (BCL2i)</b>	Ph1	-			
<b>BGB-43395 (CDK4i)</b>	Ph1	-			
<b>BG-C9074 (B7-H4 ADC)</b>	Ph1	Duality Bio			
<b>BG-75098 (CDK2 CDAC)</b>	Ph1	-			
<b>BG-75202 (KAT6A/Bi)</b>	Ph1	-			
<b>BGB-B445 (Claudin 6 x CD3 bsAb)</b>	Ph1	-			
<b>BGB-58067 (MTA Coop. PRMT5i)</b>	Ph1	-			
<b>BG-T187 (EGFR x MET x MET tsAb)</b>	Ph1	-			
<b>BG-C0979 (ADAM9 ADC)</b>	Ph1	-			
<b>BG-C0902 (EGFR x MET x MET tsADC)</b>	Ph1	-			
<b>BG-C477 (CEA ADC)</b>	Ph1	-			
<b>BG-C137 (FGFR2b ADC)</b>	Ph1	-			
<b>BGB-B2033 (GPC3 x 4-1BB bsAb)</b>	Ph1	-			
<b>BGB-26808 (HPK1i)</b>	Ph1	-			
<b>Xaluritamig (STEAP1 x CD3 XmAb)<sup>2</sup></b>	Ph1	Amgen			

<sup>1</sup> Amgen collaboration. A significant portion of our rights to receive certain tiered mid-single digit royalty payments based on annual net revenue from sales outside of China of IMDELLTRA were sold to Royalty Pharma in the third quarter of 2025

<sup>2</sup> Study is being conducted in China as part of the BeOne-Amgen collaboration

<sup>3</sup> Sonrotoclax is currently approved in China for R/R MCL and R/R CLL

<sup>4</sup> Excluding Japan and India

<sup>5</sup> Further clinical development activities planned

Please refer to our most recent 10-K filing for a full list of our commercial products, including in-licensed products, as well as commercial rights and collaboration details



# Glossary

As of: 01 May 2026

## Disease abbreviations

<b>AD</b>	Atopic dermatitis	<b>MM</b>	Multiple myeloma
<b>AML</b>	Acute myeloid leukemia	<b>MSI-H</b>	Microsatellite stability high
<b>BP-ALL</b>	B-precursor acute lymphocytic leukemia	<b>MSS CRC</b>	Microsatellite stable colorectal cancer
<b>BTC</b>	Biliary tract cancer	<b>MZL</b>	Marginal zone lymphoma
<b>CLL</b>	Chronic lymphocytic leukemia	<b>NSCLC</b>	Non-small cell lung cancer
<b>CSU</b>	Chronic spontaneous urticaria	<b>NPC</b>	Nasopharyngeal carcinoma
<b>dMMR</b>	Deficient DNA mismatch repair	<b>PMN</b>	Primary membranous nephropathy
<b>ES-SCLC</b>	Extensive stage small cell lung cancer	<b>PN</b>	Prurigo nodularis
<b>ESCC</b>	Esophageal squamous cell carcinoma	<b>PSR OC</b>	Platinum sensitive recurrent ovarian cancer
<b>FL</b>	Follicular lymphoma	<b>R/R</b>	Relapsed or refractory
<b>GEA</b>	Gastroesophageal adenocarcinoma	<b>SCLC</b>	Small cell lung cancer
<b>GC</b>	Gastric cancer	<b>SLL</b>	Small lymphocytic lymphoma
<b>HCC</b>	Hepatocellular carcinoma	<b>UC / UBC</b>	Urinary / bladder cancer
<b>HNSCC</b>	Head and neck squamous cell carcinoma	<b>WM</b>	Waldenström's macroglobulinemia
<b>LS-SCLC</b>	Limited stage small cell lung cancer		
<b>MCL</b>	Mantle cell lymphoma		
<b>mCRPC</b>	Metastatic castration resistant prostate cancer		
<b>MDS</b>	Myelodysplastic syndromes		

## Other abbreviations

<b>ADC</b>	Antibody drug conjugate	<b>MPR</b>	Major pathological response
<b>AE</b>	Adverse event	<b>MRD</b>	Minimal residual disease
<b>bsAb</b>	Bi-specific antibody	<b>MTD</b>	Maximum tolerated dose
<b>bsADC</b>	Bi-specific antibody drug conjugate	<b>MTx</b>	Maintenance
<b>BITE®</b>	Bi-specific T-cell engager	<b>NME</b>	New Molecular Entity
<b>CDAC</b>	Chimeric degradation activation compound	<b>ORR</b>	Objective response rate
<b>CR</b>	Complete response	<b>OS</b>	Overall survival
<b>CRh</b>	Complete remission with partial hematological recovery	<b>PCR</b>	Pathologic complete response
<b>DCR</b>	Disease control rate	<b>PFS</b>	Progression-free survival
<b>DLT</b>	Dose-limiting toxicity	<b>RDFE</b>	Recommended dose for expansion
<b>DOR</b>	Duration of response	<b>RP2D</b>	Recommended phase 2 dose
<b>EFS</b>	Event free survival	<b>SAE</b>	Severe adverse event
<b>HV</b>	Healthy volunteers	<b>TEAE</b>	Treatment emergent adverse event
<b>IITs</b>	Investigator-Initiated Trials	<b>TN</b>	Treatment naïve
<b>LCM</b>	Lifecycle management	<b>tsAb</b>	Tri-specific antibody
<b>LTE</b>	Long-term extension	<b>tsADC</b>	Tri-specific antibody drug conjugate
<b>mAb</b>	Monoclonal antibody	<b>VGPR</b>	Very good partial response
<b>mOR</b>	Modified overall response	<b>XmAb®</b>	XmAb is a registered trademark of Xencor, Inc.

